CEO provides brief update to Proactive Investors

AdAlta CEO Sam Cobb spoke with Proactive Investors during her recent trip to San Francisco to attend Biotech Showcase, meeting with investors and pharmaceutical companies.

Take a look at the brief interview below which provides an update on the progress of AdAlta’s lead program, AD-214, a novel i-body therapy for the treatment of the lung condition, Idiopathic Pulmonary Fibrosis.

If you would like to stay informed of AdAlta’s progress, subscribe to receive updates here.